Co-Diagnostics, Inc., founded with a mission to improve global health through advanced molecular diagnostics, specializes in developing and selling nucleic acid tests and diagnostic lab systems. The company offers the Co-Dx™ PCR platform, which represents a significant advancement in PCR technology, providing affordable and accessible on-site testing solutions. Their products are designed to detect and analyze nucleic acid molecules, addressing critical healthcare needs worldwide.
Notable affiliated individuals and investors include key figures in the biotechnology and healthcare sectors, though specific names are not provided. Co-Diagnostics has achieved significant milestones, such as the development of the Co-Dx™ PCR Pro™, which has transformed healthcare diagnostics by making PCR testing more affordable and accessible. The company's impact is evident in its global reach and commitment to making life-saving diagnostics available to those in need, particularly in regions with high disease burdens like India.
